O
Orum Therapeutics
Private biotech company creating cell penetrating therapeutic antibodies
About Orum Therapeutics
Orum Therapeutics is a clinical-stage biotechnology company founded in 2016 with operations in Daejeon, South Korea, and Boston, US, developing degrader-antibody conjugates (DACs) for cancer treatment. Its Dual-Precision Targeted Protein Degradation (TPD²) platform combines antibodies with targeted protein degraders to act on tumour cells, and its lead candidate ORM-6151, an anti-CD33 antibody-enabled GSPT1 degrader, is being developed for acute myeloid leukaemia. The company holds a global multi-target licence and option agreement with Vertex Pharmaceuticals, and listed on the KOSDAQ market in February 2025, with its shares trading under code 475830.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2016
- Headquarters
- Lexington, United States
- Listing
- IPO 2025
- Employees
- 54
- Open positions
- None listed
- Dealroom signal
- 76.1/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO CONVERTIBLE✓Other financing | Jan 2026 | $204M | — | Undisclosed | ↗ |
| POST IPO CONVERTIBLE✓Other financing | Dec 2025 | $100M | — | Stassets Investment · Weiss Asset Management · DSC Investment · Korea Investment Partners | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin | Profit | Margin |
|---|---|---|---|---|---|---|
| 2026 | $20K | 0% | −$41M | -205696.6% | −$35M | -178137.1% |
| 2025 | $20K | -99.9% | −$41M | -205696.6% | −$35M | -178137.1% |
| 2024 | $18M | -84.6% | — | — | — | — |
| 2023 | $114M | +178267.2% | — | — | — | — |
| 2022 | $64K | — | — | — | — | — |
Growth signals
Latest recorded traffic for Orum Therapeutics is 5.7K monthly website visits, down 75.2% over the last three months. Orum Therapeutics's team grew 5.9% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A16 investors entered at this stage
InterVest
Solidus Investment
IMM Investment
SmileGate Investment- DNDaol Investment (Formerly KTB Network)
KB Investment
KDB Investment
Atinum Investment- SIStassets Investment
Weiss Asset Management
DSC Investment
Korea Investment Partners
DAYLI Partners
Company K Partners
Woori Venture Partners
AON Investment
Other known investors3 additional known investors
Ajou University
LB Investment
Premier Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Orum Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Orum Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.